RAS-Mutant PDAC: Testing, Treatment Strategies and Future Directions

Panelists discuss RAS mutations in pancreatic cancer, focusing on prevalence and testing, evolving second-line treatment strategies including emerging targeted agents like daraxonrasib, and key ASCO 2025 highlights and future perspectives in pancreatic ductal adenocarcinoma (PDAC).

EP. 1: Targeting RAS: A Critical Oncogenic Pathway Across Tumor Types

June 17th 2025

Panelists discuss how KRAS mutations, long considered “undruggable” in pancreatic cancer, are now emerging as actionable targets thanks to allele-specific inhibitors, marking a turning point in precision oncology and offering new hope for improving outcomes in a historically treatment-resistant disease.

EP. 2: Decoding RAS Mutations: How KRAS Leads in Pancreatic Malignancies

June 17th 2025

Panelists discuss how advancements in molecular oncology are transforming RAS mutations—especially KRAS, but also NRAS and HRAS—from historically “undruggable” targets into promising avenues for personalized therapy in pancreatic and other solid tumors.

EP. 3: Molecular Profiling in Pancreatic Cancer: RAS Testing and Codon-Specific Interpretation

June 24th 2025

Panelists highlighted how recent breakthroughs in KRAS-specific inhibitors—such as those targeting G12C, G12D, and G12V mutations—are transforming the management of pancreatic cancer, underscoring the importance of precise molecular profiling through tumor-based next-generation sequencing or, when necessary, circulating tumor DNA to guide emerging personalized therapies in this historically challenging disease.

EP. 4: KRAS in mPDAC: Timing and Value of Testing Amid Limited Treatment

June 24th 2025

Panelists emphasized that early, comprehensive molecular testing at diagnosis—including for RAS mutations—is essential in pancreatic cancer to uncover rare but actionable targets, facilitate timely clinical trial enrollment, and build a foundation for future treatment decisions, even if no immediate therapies are available.

EP. 5: Treatment After Progression: Navigating Second-Line Options in KRAS-Mutant Pancreatic Cancer

July 1st 2025

Panelists discussed second-line treatment for RAS-mutant pancreatic cancer, emphasizing that sequencing regimens like FOLFIRINOX and gemcitabine-based therapies should be tailored to prior treatment and performance status, while also integrating holistic care—including pain management, nutrition, and early use of molecularly targeted agents—to maximize quality of life and capitalize on critical therapeutic windows.

EP. 6: RAS-ON vs RAS-OFF inhibitors in PDAC: Exploring Daraxonrasib

July 1st 2025

Recent breakthroughs in pancreatic cancer treatment focus on novel inhibitors that target the active, GTP-bound “RAS-ON” state—previously considered undruggable—showing promising early trial results with meaningful response rates, reduced circulating tumor DNA, and extended progression-free survival, signaling a potential paradigm shift in managing this historically difficult-to-treat disease.

EP. 7: ASCO 2025 Spotlight: RASolute 302 Trial Design and Daraxonrasib’s Clinical Potential

July 8th 2025

A new phase 3 trial evaluating an oral RAS-ON inhibitor in patients with advanced pancreatic cancer after frontline chemotherapy marks a major step toward potentially redefining second-line treatment, offering a targeted, patient-friendly alternative to standard chemotherapy with the hope of improving both outcomes and quality of life.

EP. 8: The Future of mPDAC: New Hope With RAS-ON Inhibitors and Emerging Strategies

July 8th 2025

After decades of limited progress, a new wave of RAS-targeted therapies—backed by stronger early-phase data and smarter trial design—is driving renewed optimism in pancreatic cancer, offering the real possibility of more effective, better-tolerated, and personalized treatment options for a disease long defined by therapeutic scarcity.

EP. 9: ASCO 2025 PDAC Highlights: Key Advances and Emerging Data

July 8th 2025

Despite recent breakthroughs, a major unmet need in pancreatic cancer remains extending effective therapies to patients without targetable mutations—requiring more precise molecular stratification, strategic combinations (including immunotherapy), and a continued focus on durable responses through clinical trial participation to truly transform outcomes in this heterogeneous and historically resistant disease.

x